CTGov Compliance My Organizations

Compliance Rate

Compliance Rate 0%

Compliant submissions 0

Incompliant submissions 0

Total trials 0

My Organizations' Clinical Trials

Showing 138 of 138 entries

View as:

A Phase I/II Trial to Assess the Safety and Tolerance of Escalating Doses of a Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Retinitis

Phase: N/A Priority: Normal

NCT ID: NCT00002016 Org: User:

Start: - End: - Due: -

To Demonstrate the Relative Bioequivalency Study of Dosage Forms of Clemastine 2.68 mg Tablets

Phase: N/A Priority: Normal

NCT ID: NCT00913549 Org: User:

Start: 12/31/89 End: 01/31/90 Due: 01/31/91

To Demonstrate the Relative Bioavailability of Cilostazol 50 mg Tablets Under Fasting Conditions

Phase: N/A Priority: Normal

NCT ID: NCT00881231 Org: User:

Start: 01/31/04 End: 02/29/04 Due: 02/28/05

Remission of ICD by Switching Dopamine Agonist to Levodopa/Carbidopa

Phase: N/A Priority: Normal

NCT ID: NCT01683253 Org: User:

Start: 11/30/12 End: 12/31/14 Due: 12/31/15

GP2013 in Japanese Patients With CD20 Positive Low Tumor Burden Indolent B-cell Non-Hodgkin's Lymphoma

Phase: N/A Priority: Normal

NCT ID: NCT01933516 Org: User:

Start: 05/31/13 End: 08/31/14 Due: 08/31/15

Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor

Phase: N/A Priority: Normal

NCT ID: NCT01459653 Org: User:

Start: 03/31/10 End: 08/31/13 Due: 08/31/14

Bioavailability of Oxymorphone Hydrochloride 40 mg Extended Release Tablets Under Fasted Conditions

Phase: N/A Priority: Normal

NCT ID: NCT00857428 Org: User:

Start: 11/30/07 End: 12/31/07 Due: 12/31/08

To Demonstrate the Relative Bioavailability of Atenolol Tablets, 100 mg

Phase: N/A Priority: Normal

NCT ID: NCT00946725 Org: User:

Start: 11/30/00 End: 11/30/00 Due: 11/30/01

To Demonstrate the Relative Bioavailability of Cefzil 250 mg/5 ml Cefprozil Oral Suspension Following a 10 ml Dose Fasting Conditions.

Phase: N/A Priority: Normal

NCT ID: NCT00881153 Org: User:

Start: 05/31/04 End: 06/30/04 Due: 06/30/05

Immunogenicity, Safety, and Efficacy of Zarzio®/Filgrastim HEXAL® in Patients With Severe Chronic Neutropenia

Phase: N/A Priority: Normal

NCT ID: NCT01859637 Org: User:

Start: 07/31/11 End: 09/30/15 Due: 09/30/16

Study of Loteprednol Etabonate in Adults Undergoing Bilateral Cataract Surgery

Phase: N/A Priority: Normal

NCT ID: NCT03531697 Org: User:

Start: 04/26/18 End: 10/07/19 Due: 10/07/20

To Demonstrate the Relative Bioavailability of Clarithromycin 250 mg Tablets Under Fasting Conditions

Phase: N/A Priority: Normal

NCT ID: NCT00881738 Org: User:

Start: 06/30/02 End: 07/31/02 Due: 07/31/03

To Demonstrate the Effect of Food on the Bioavailability of Glipizide

Phase: N/A Priority: Normal

NCT ID: NCT00947024 Org: User:

Start: 11/30/93 End: 11/30/93 Due: 11/30/94

Title	NCT ID	Organization	User	Status	Start Date	End Date	Reporting Due Date	Last Checked	User Role	Org Created
A Phase I/II Trial to Assess the Safety and Tolerance of Escalating Doses of a Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Retinitis	NCT00002016	Sandoz	user2@example.com	None	-	-	-	-	-	2025-07-14
To Demonstrate the Relative Bioequivalency Study of Dosage Forms of Clemastine 2.68 mg Tablets	NCT00913549	Sandoz	user2@example.com	None	1989-12-31	1990-01-31	1991-01-31	-	-	2025-07-14
To Demonstrate the Relative Bioavailability of Cilostazol 50 mg Tablets Under Fasting Conditions	NCT00881231	Sandoz	user2@example.com	None	2004-01-31	2004-02-29	2005-02-28	-	-	2025-07-14
Remission of ICD by Switching Dopamine Agonist to Levodopa/Carbidopa	NCT01683253	Sandoz	user2@example.com	None	2012-11-30	2014-12-31	2015-12-31	-	-	2025-07-14
GP2013 in Japanese Patients With CD20 Positive Low Tumor Burden Indolent B-cell Non-Hodgkin's Lymphoma	NCT01933516	Sandoz	user2@example.com	None	2013-05-31	2014-08-31	2015-08-31	-	-	2025-07-14
Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor	NCT01459653	Sandoz	user2@example.com	None	2010-03-31	2013-08-31	2014-08-31	-	-	2025-07-14
Bioavailability of Oxymorphone Hydrochloride 40 mg Extended Release Tablets Under Fasted Conditions	NCT00857428	Sandoz	user2@example.com	None	2007-11-30	2007-12-31	2008-12-31	-	-	2025-07-14
To Demonstrate the Relative Bioavailability of Atenolol Tablets, 100 mg	NCT00946725	Sandoz	user2@example.com	None	2000-11-30	2000-11-30	2001-11-30	-	-	2025-07-14
To Demonstrate the Relative Bioavailability of Cefzil 250 mg/5 ml Cefprozil Oral Suspension Following a 10 ml Dose Fasting Conditions.	NCT00881153	Sandoz	user2@example.com	None	2004-05-31	2004-06-30	2005-06-30	-	-	2025-07-14
Immunogenicity, Safety, and Efficacy of Zarzio®/Filgrastim HEXAL® in Patients With Severe Chronic Neutropenia	NCT01859637	Sandoz	user2@example.com	None	2011-07-31	2015-09-30	2016-09-30	-	-	2025-07-14
Study of Loteprednol Etabonate in Adults Undergoing Bilateral Cataract Surgery	NCT03531697	Sandoz	user2@example.com	None	2018-04-26	2019-10-07	2020-10-07	-	-	2025-07-14
To Demonstrate the Relative Bioavailability of Clarithromycin 250 mg Tablets Under Fasting Conditions	NCT00881738	Sandoz	user2@example.com	None	2002-06-30	2002-07-31	2003-07-31	-	-	2025-07-14
To Demonstrate the Effect of Food on the Bioavailability of Glipizide	NCT00947024	Sandoz	user2@example.com	None	1993-11-30	1993-11-30	1994-11-30	-	-	2025-07-14

Compliance Rate

My Organizations' Clinical Trials

Appearance